

Board of Pharmacy Specialties

2215 Constitution Avenue, NW • Washington, DC 20037 • (202) 429-7591 • (202) 429-6304 FAX • www.bpsweb.org

FOR IMMEDIATE RELEASE:

June 1, 2012

Contact: Steve Scarlata

info@bpsweb.org; 202-429-6306

BPS Announces Cardiology and Infectious Diseases Practice Analysis Taskforce Appointments

Washington, DC – The [Board of Pharmacy Specialties](http://www.bpsweb.org) (BPS) recently approved role delineation studies in Cardiology and Infectious Diseases. Conducting a role delineation study is a critical step in evaluating a proposed specialty. The purpose of the role delineation study is to determine whether these practice areas are based upon specialized knowledge of the pharmaceutical sciences, as well as specialized functions routinely performed by practitioners in these proposed specialties.

BPS is pleased to announce the members of the Practice Analysis Taskforce in **Infectious Diseases** are:

- **Craig Martin, PharmD, BCPS (AQ-ID)**, Pharmacist Specialist-Infectious Diseases, UK Healthcare, and Associate Professor, University of Kentucky College of Pharmacy, Lexington, KY
- **Douglas Slain, PharmD, BCPS (AQ-ID), FCCP, FASHP**, Associate Professor and Clinical Specialist, West Virginia University, Morgantown, WV
- **Rachel Chambers, PharmD, BCPS (AQ-ID)**, Pharmacy Specialist, Antimicrobial Stewardship, Henry Ford Hospital, Detroit, MI
- **Russell Benefield, PharmD, BCPS**, Clinical Pharmacist, Infectious Diseases, University of Utah Hospital, Salt Lake City, UT
- **Marisel Segarra-Newnham, PharmD, MPH, FCCP, BCPS**, Clinical Pharmacy Specialist in Infectious Disease/HIV, VA Medical Center, West Palm Beach, FL, and Clinical Assistant Professor, University of Florida College of Pharmacy, Gainesville, FL
- **Kerry LaPlante, PharmD**, Infectious Disease Pharmacotherapy Specialist, Veterans Affairs Medical Center, and Associate Professor, University of Rhode Island, Providence, RI
- **David T. Bearden, PharmD**, Associate Professor and Chair, Pharmacy Practice, Oregon State University College of Pharmacy, Portland, OR
- **Kari Mergenhagen, PharmD, BCPS (AQ-ID)**, Infectious Disease Clinical Pharmacy Specialist, WNY VA Healthcare System, Buffalo, NY
- **Jarrold Kile, R.Ph., BCPS**, Clinical Pharmacy Specialist-Antibiotic Stewardship Program, Infectious Disease, Lehigh Valley Health Network, Allentown, PA
- **John D. Cleary, PharmD, FCCP, BCPS (AQ-ID)**, Professor, University of Mississippi School of Pharmacy, Jackson, MS
- **Jennifer Le, PharmD, FCCP, BCPS (AQ-ID)**, Associate Professor of Clinical Pharmacy, University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA

The members of the Practice Analysis Taskforce in **Cardiology** are:

- **Joel Marrs, PharmD, CLS, BCPS (AQ-Cardiology)**, Assistant Professor, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO and Clinical Pharmacy Specialist, Denver Health Medical Center, Denver, CO
- **Sara Brouse, PharmD, FCCP, BCPS (AQ-Cardiology)**, Cardiology Clinical Specialist, University of Kentucky Healthcare, Lexington, KY

- **David S. Roffman, PharmD, BCPS (AQ-Cardiology)**, Professor Pharmacy Practice and Science, University of Maryland School of Pharmacy/Therapeutic Consultant, Division of Cardiology, University of Maryland Medical System, Baltimore, MD
- **Robert Lee Page, PharmD, MSPH, FCCP, FAHA, FASHP, FASCP, BCPS, CGP**, Associate Professor, University of Colorado School of Pharmacy and School of Medicine, Aurora, CO
- **Paul P. Dobesh, PharmD, FCCP, BCPS (AQ-Cardiology)**, Associate Professor of Pharmacy Practice, University of Nebraska College of Pharmacy, Omaha, NE
- **Mike Dorsch, PharmD, MS, BCPS (AQ-CV)**, Clinical Pharmacist, Cardiology, University of Michigan, Ann Arbor, MI
- **Anne Schullo-Feulner, PharmD, BCPS**, Clinical Specialist, Methodist Hospital, and Assistant Professor, University of Minnesota, Minneapolis, MN
- **Carrie Oliphant, PharmD, BCPS (AQ-Cardiology)**, Cardiology and Anticoagulation Clinical Specialist, Methodist University Hospital, Memphis, TN, and Associate Professor, University of Tennessee College of Pharmacy
- **John Lindsley, PharmD, BCPS**, Clinical Pharmacy Specialist, Cardiology, The Johns Hopkins Hospital, Baltimore, MD, and Clinical Assistant Professor, University of Maryland School of Pharmacy, Baltimore, MD
- **Freddy M. Tadros, PharmD, BCPS**, Clinical Pharmacy Specialist, Cardiology, James A. Haley Veterans Affairs Hospital, Tampa, FL

The initial work of each practice analysis taskforce will be reviewed by an outside panel of subject matter experts and then validated via a survey administered to pharmacists practicing in each area. If the role delineation studies in these two areas yield information suggestive that Cardiology and/or Infectious Diseases should be recognized as a specialty practice in pharmacy, BPS will then issue a call to the profession for a petition for new specialty recognition. The complete process leading to the administration of a certification exam in a new specialty takes approximately three years to complete.

For more information on BPS activities including applying for the 2012 examination visit www.bpsweb.org

About the Board of Pharmacy Specialties

The [Board of Pharmacy Specialties](http://www.bpsweb.org) (BPS), an autonomous division of the American Pharmacists Association (APhA), was founded in January 1976 to recognize specialties and certify pharmacists in specialized areas of pharmacy practice. Six specialties are currently recognized by BPS, including: 1) nuclear pharmacy, since 1978; 2) nutrition support pharmacy, since 1988; 3) pharmacotherapy, since 1988; 4) psychiatric pharmacy, since 1992; and 5) oncology pharmacy, since 1996. The latest BPS specialty, focused on ambulatory care pharmacy, was approved in June 2009, and the first examination was administered in 2011. Currently 12,900 pharmacist specialists are certified by BPS.
